<?xml version="1.0" encoding="UTF-8"?>
<p id="p0030">The other RdRp inhibitor favipiravir (Fujifilm Toyama Chemical Co. Ltd, Tokyo, Japan) is known to be active 
 <italic>in vitro</italic> against oseltamivir-resistant influenza A, B, and C viruses.
 <xref rid="bib26" ref-type="bibr">
  <sup>26</sup>
 </xref> After being converted into an active phosphoribosylated form, favipiravir is easily recognized as a substrate of viral RNA polymerase in many RNA viruses.
 <xref rid="bib27" ref-type="bibr">
  <sup>27</sup>
 </xref> The recommended dose of favipiravir against influenza virus is 1600 mg administered orally twice daily on day 1, then 600 mg orally twice daily on day 2–5, and 600 mg once on day 6. Recently, preliminary results of clinical studies have shown favipiravir to have promising potency in treatment of Chinese patients with SARS-CoV-2 infection.
 <xref rid="bib28" ref-type="bibr">
  <sup>28</sup>
 </xref> Favipiravir was approved for the treatment of COVID-19 in China in March, 2020. In addition, patients with COVID-19 infection are being recruited for randomized trials to evaluate the efficacy of favipiravir plus interferon-α (ChiCTR2000029600) and favipiravir plus baloxavir marboxil (ChiCTR2000029544).
</p>
